Interleukin-17A

Description:

Description
  • Accession: Q16552
  • Swissprot: IL17_HUMAN
  • Organism: Homo sapiens
  • Gene: IL17A
  • Target class: Cytokine

Drug Relations:

ixekizumab
A humanized anti-interleukin 17 monoclonal antibody used for the treatment of PSORIASIS. Bioactivity details MOA
secukinumab
Secukinumab is a human IgG1 monoclonal antibody that selectively binds to the interleukin-17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Secukinumab inhibits the release of proinflammatory cytokines and chemokines. Bioactivity details MOA